Table 1.
Clinical information. Data are presented as first visit (second visit) scores on each clinical instrument. Note: Bolded PiB values deemed amyloid positive; * closest PiB PET performed 2 years after baseline assessment; ** closest PiB PET performed 2 years prior to baseline assessment; MoCA = Montreal Cognitive Assessment; FAB = Frontal Assessment Battery; WAB AQ = Western Aphasia Battery, Revised Aphasia Quotient; BNT = Boston Naming Test, short form; NAT = Northwestern Anagram Test; ASRS-3 = AOS Rating Scale, version 3; MDS-UPDRS 3 = The Movement Disorders Society-sponsored version of the Unified Parkinson’s Disease Rating Scale motor subsection; PSIS = Progressive Supranuclear Palsy (PSP) Saccadic Impairment scale1; PSPRS = PSP Rating Scale; NA = Not administered. Maximum scores noted in column header.
| Sex | Global PiB |
MoCA (/30) |
FAB (/18) |
WAB AQ (/100) |
BNT (/15) |
NAT (/10) |
ASRS - 3 (/52) |
Aphasia Severity (/4) |
Apraxia Severity (/4) |
MDS- UPDRS 3 (/120) |
PSIS (/5) |
PSPRS (/100) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 1.272 | 28 (17) | 16 (12) | 81 (75) | NA (13) | 8 (6) | 38 (35) | 1.5 (2.0) | 4.0 (4.0) | 16(32) | 2(1) | 13(32) |
| 2 | M | 1.327 | 29 (28) | 17 (15) | 98 (92) | 15 (14) | 10 (10) | 9 (12) | 0.0 (0.5) | 1.0 (1.0) | 18(33) | 1(1) | 15(22) |
| 3 | F | 1.494* | 30 (27) | 16 (15) | 97 (NA) | 15 (15) | 7 (NA) | 29 (40) | 0.5 (NA) | 3.0 (4.0) | 13(45) | 1(2) | 9(44) |
| 4 | M | 1.239 | 29 (30) | NA (17) | 100 (100) | 15 (15) | 10 (10) | 17 (21) | 0.0 (0.0) | 1.5 (2.0) | NA(22) | 0(0) | NA(12) |
| 5 | M | 1.407** | 28 (24) | 15 (NA) | 98 (99) | 15 (15) | 10 (10) | 24 (27) | 0.0 (0.5) | 2.5 (3.0) | 8(NA) | 1(NA) | 10(NA) |
| 6 | M | 1.654 | 27 (29) | 14 (15) | 98 (94) | 15 (15) | 10 (10) | 22 (15) | 0.0 (1.0) | 3.0 (3.0) | 45(47) | 2(2) | 32(36) |
| 7 | F | 1.476 | 21 (19) | 15 (15) | 97 (83) | 11 (11) | 7 (4) | 26 (35) | 1.0 (1.5) | 2.0 (3.5) | 10(36) | 1(1) | 20(35) |
| 8 | M | 1.437 | 25 (8) | 15 (7) | 85 (NA) | 15 (NA) | 4 (0) | 28 (27) | 1.0 (2.5) | 3.5 (4.0) | 25(48) | 0(0) | 28(46) |
| 9 | M | 1.216 | 28 (25) | 14 (14) | 99 (99) | 14 (14) | 10 (10) | NA (23) | 0.5 (0.0) | 2.0 (2.5) | 17(30) | 2(3) | 17(29) |
| 10 | F | 1.944 | 26 (23) | 17 (15) | 95 (90) | NA (14) | 10 (9) | 29 (30) | 0.0 (1.0) | 3.0 (3.5) | 16(43) | 0(2) | 21(40) |
| 11 | F | 1.298 | 30 (26) | 17 (17) | 97 (98) | NA (13) | 8 (9) | 20 (39) | 1.0 (0.0) | 2.0 (4.0) | 18(35) | 0(1) | 12(27) |
| 12 | M | 2.999 | 26 (17) | 16 (17) | 92 (93) | NA (13) | 8 (4) | 16 (13) | 1.0 (2.0) | 2.0 (1.0) | 10(11) | 0(0) | 4(7) |
| 13 | F | 1.399 | 29 (25) | 13 (13) | 98 (NA) | 14 (15) | 8 (NA) | 18 (19) | 0.0 (NA) | 1.5 (1.5) | 23(32) | 2(3) | 13(33) |
PSIS score of 1 = mild slowing of vertical saccades; 2 = moderate slowing of vertical saccades; 3 = vertical supranuclear gaze palsy